A citation-based method for searching scientific literature

Yijun Jia, Tao Jiang, Xuefei Li, Chao Zhao, Limin Zhang, Sha Zhao, Xiaozhen Liu, Meng Qiao, Jiawei Luo, Jinpeng Shi, Hui Yang, Yan Wang, Lei Xi, Shijia Zhang, Guanghui Gao, Chunxia Su, Shengxiang Ren, Caicun Zhou. Oncol Lett 2017
Times Cited: 22







List of co-cited articles
251 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, Jian Su, Zhi Xie, Si-Yang Liu, Hai-Yan Tu, Hua-Jun Chen, Yue-Li Sun, Qing Zhou,[...]. Clin Cancer Res 2017
449
54

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
694
45

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Ferdinandos Skoulidis, Lauren A Byers, Lixia Diao, Vassiliki A Papadimitrakopoulou, Pan Tong, Julie Izzo, Carmen Behrens, Humam Kadara, Edwin R Parra, Jaime Rodriguez Canales,[...]. Cancer Discov 2015
468
40

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Nathan T Ihle, Lauren A Byers, Edward S Kim, Pierre Saintigny, J Jack Lee, George R Blumenschein, Anne Tsao, Suyu Liu, Jill E Larsen, Jing Wang,[...]. J Natl Cancer Inst 2012
323
36

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Nan Chen, Wenfeng Fang, Zhong Lin, Peijian Peng, Juan Wang, Jianhua Zhan, Shaodong Hong, Jiaxing Huang, Lin Liu, Jin Sheng,[...]. Cancer Immunol Immunother 2017
132
36

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.
Kathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, Jordan Dienstag, Helena A Yu, Francisco Sanchez-Vega, Piro Lito, Michael Berger, David B Solit, Matthew Hellmann,[...]. Clin Cancer Res 2018
173
36

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Snjezana Dogan, Ronglai Shen, Daphne C Ang, Melissa L Johnson, Sandra P D'Angelo, Paul K Paik, Edyta B Brzostowski, Gregory J Riely, Mark G Kris, Maureen F Zakowski,[...]. Clin Cancer Res 2012
353
36

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Jill Hallin, Lars D Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R Baer, Joshua A Ballard,[...]. Cancer Discov 2020
418
36

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
Frances A Shepherd, Caroline Domerg, Pierre Hainaut, Pasi A Jänne, Jean-Pierre Pignon, Stephen Graziano, Jean-Yves Douillard, Elizabeth Brambilla, Thierry Le Chevalier, Lesley Seymour,[...]. J Clin Oncol 2013
200
31

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Ernest Nadal, Guoan Chen, John R Prensner, Hiroe Shiratsuchi, Christine Sam, Lili Zhao, Gregory P Kalemkerian, Dean Brenner, Jules Lin, Rishindra M Reddy,[...]. J Thorac Oncol 2014
69
31

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer.
M C Garassino, M Marabese, P Rusconi, E Rulli, O Martelli, G Farina, A Scanni, M Broggini. Ann Oncol 2011
142
31


STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
660
31

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Matthew R Janes, Jingchuan Zhang, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Xin Guo, Yuching Chen, Anjali Babbar, Sarah J Firdaus, Levan Darjania,[...]. Cell 2018
489
31

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Arnaud Jeanson, Pascale Tomasini, Maxime Souquet-Bressand, Nicolas Brandone, Mohamed Boucekine, Mathieu Grangeon, Solène Chaleat, Natalyia Khobta, Julie Milia, Laurent Mhanna,[...]. J Thorac Oncol 2019
80
31

The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Chengming Liu, Sufei Zheng, Runsen Jin, Xinfeng Wang, Feng Wang, Ruochuan Zang, Haiyan Xu, Zhiliang Lu, Jianbing Huang, Yuanyuan Lei,[...]. Cancer Lett 2020
89
31

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Pasi A Jänne, Michel M van den Heuvel, Fabrice Barlesi, Manuel Cobo, Julien Mazieres, Lucio Crinò, Sergey Orlov, Fiona Blackhall, Juergen Wolf, Pilar Garrido,[...]. JAMA 2017
208
27

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
M B Schabath, E A Welsh, W J Fulp, L Chen, J K Teer, Z J Thompson, B E Engel, M Xie, A E Berglund, B C Creelan,[...]. Oncogene 2016
159
27

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Matthew P Patricelli, Matthew R Janes, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Linda V Kessler, Yuching Chen, Jeff M Kucharski, Jun Feng, Tess Ely,[...]. Cancer Discov 2016
375
27

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Alona Zer, Keyue Ding, Siow Ming Lee, Glenwood D Goss, Lesley Seymour, Peter M Ellis, Allan Hackshaw, Penelope A Bradbury, Lei Han, Christopher J O'Callaghan,[...]. J Thorac Oncol 2016
40
27

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Matthias Scheffler, Michaela A Ihle, Rebecca Hein, Sabine Merkelbach-Bruse, Andreas H Scheel, Janna Siemanowski, Johannes Brägelmann, Anna Kron, Nima Abedpour, Frank Ueckeroth,[...]. J Thorac Oncol 2019
87
27

Drugging the undruggable RAS: Mission possible?
Adrienne D Cox, Stephen W Fesik, Alec C Kimmelman, Ji Luo, Channing J Der. Nat Rev Drug Discov 2014
27

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
373
27

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
Rodrigo Romero, Volkan I Sayin, Shawn M Davidson, Matthew R Bauer, Simranjit X Singh, Sarah E LeBoeuf, Triantafyllia R Karakousi, Donald C Ellis, Arjun Bhutkar, Francisco J Sánchez-Rivera,[...]. Nat Med 2017
286
22

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Jonathan M Ostrem, Ulf Peters, Martin L Sos, James A Wells, Kevan M Shokat. Nature 2013
22

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
P A Jänne, I Smith, G McWalter, H Mann, B Dougherty, J Walker, M C M Orr, D R Hodgson, A T Shaw, J R Pereira,[...]. Br J Cancer 2015
60
22

A comprehensive survey of Ras mutations in cancer.
Ian A Prior, Paul D Lewis, Carla Mattos. Cancer Res 2012
22

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.
Marta Román, Iosune Baraibar, Inés López, Ernest Nadal, Christian Rolfo, Silvestre Vicent, Ignacio Gil-Bazo. Mol Cancer 2018
154
22


Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
Helena Linardou, Issa J Dahabreh, Dimitra Kanaloupiti, Fotios Siannis, Dimitrios Bafaloukos, Paris Kosmidis, Christos A Papadimitriou, Samuel Murray. Lancet Oncol 2008
592
18

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.
C Mascaux, N Iannino, B Martin, M Paesmans, T Berghmans, M Dusart, A Haller, P Lothaire, A-P Meert, S Noel,[...]. Br J Cancer 2005
439
18

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
18

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases.
Taebum Lee, Boram Lee, Yoon-La Choi, Joungho Han, Myung-Ju Ahn, Sang-Won Um. J Pathol Transl Med 2016
59
18

KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.
Weimin Gao, Jide Jin, Jinling Yin, Stephanie Land, Autumn Gaither-Davis, Neil Christie, James D Luketich, Jill M Siegfried, Phouthone Keohavong. Mol Carcinog 2017
17
23

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Jeffrey A Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R Guimaraes, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A Perera, Youngchul Song,[...]. Nat Med 2008
18

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Shohei Koyama, Esra A Akbay, Yvonne Y Li, Amir R Aref, Ferdinandos Skoulidis, Grit S Herter-Sprie, Kevin A Buczkowski, Yan Liu, Mark M Awad, Warren L Denning,[...]. Cancer Res 2016
302
18


RAS oncogenes: weaving a tumorigenic web.
Yuliya Pylayeva-Gupta, Elda Grabocka, Dafna Bar-Sagi. Nat Rev Cancer 2011
18

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Gregory J Riely, Mark G Kris, Daniel Rosenbaum, Jenifer Marks, Allan Li, Dhananjay A Chitale, Khedoudja Nafa, Elyn R Riedel, Meier Hsu, William Pao,[...]. Clin Cancer Res 2008
387
18

KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Wouter W Mellema, Anne-Marie C Dingemans, Erik Thunnissen, Peter J F Snijders, Jules Derks, Daniëlle A M Heideman, Robertjan Van Suylen, Egbert F Smit. J Thorac Oncol 2013
28
18

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
Kevin Wood, Thomas Hensing, Raeva Malik, Ravi Salgia. JAMA Oncol 2016
91
18


The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Benjamin Izar, Haiyu Zhou, Rebecca S Heist, Christopher G Azzoli, Alona Muzikansky, Emily E F Scribner, Lindsay A Bernardo, Dora Dias-Santagata, Anthony J Iafrate, Michael Lanuti. J Thorac Oncol 2014
56
18

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Jacqueline V Aredo, Sukhmani K Padda, Christian A Kunder, Summer S Han, Joel W Neal, Joseph B Shrager, Heather A Wakelee. Lung Cancer 2019
47
18

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
Badi El Osta, Madhusmita Behera, Sungjin Kim, Lynne D Berry, Gabriel Sica, Rathi N Pillai, Taofeek K Owonikoko, Mark G Kris, Bruce E Johnson, David J Kwiatkowski,[...]. J Thorac Oncol 2019
77
18

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.
Pascale Tomasini, Preet Walia, Catherine Labbe, Kevin Jao, Natasha B Leighl. Oncologist 2016
66
18

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
S Li, L Li, Y Zhu, C Huang, Y Qin, H Liu, L Ren-Heidenreich, B Shi, H Ren, X Chu,[...]. Br J Cancer 2014
141
13

The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.
Anna Biernacka, Peter D Tsongalis, Jason D Peterson, Francine B de Abreu, Candice C Black, Edward J Gutmann, Xiaoying Liu, Laura J Tafe, Christopher I Amos, Gregory J Tsongalis. Cancer Genet 2016
32
13

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.
Anurag Singh, Patricia Greninger, Daniel Rhodes, Louise Koopman, Sheila Violette, Nabeel Bardeesy, Jeff Settleman. Cancer Cell 2009
582
13

The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
Martin Svaton, Ondrej Fiala, Milos Pesek, Zbynek Bortlicek, Marek Minarik, Lucie Benesova, Ondrej Topolcan. Anticancer Res 2016
21
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.